ALA on the Pathway to Phase I Clinical Trials

Our biotech investment, Arovella Therapeutics (ASX:ALA), is one of only a handful of companies in the world working on an iNKT cell therapy for cancer.

ASX MedTech Junior Displays Promise for Pancreatic Cancer Patients

OncoSil Medical (ASX: OSL) has developed a first-in-class, truly innovative device that treats unresectable locally advanced pancreatic cancer — that is, tumours that can’t be surgically removed.

ASX Junior Has Early Success With K9 Cancer Trials: Human Trials Await

One ASX listed clinical stage oncology company is developing novel targeted cancer therapeutics for both humans and animals.

IMU Poised to Break into Oncolytic Virotherapy Space with Novel Cancer Therapy

The proposal for the exclusive license of patents covering the CF33 OV technology will be put to Imugene (ASX:IMU) shareholders for their approval at an Extraordinary Meeting of Shareholders to be held on 18 November.

GTG Signs Prestigious Collaboration Agreement for Fight Against Cancer

Emerging med-tech junior Genetic Technologies (ASX:GTG | NASDAQ:GENE) understands the importance of timely and precise targeting. Accessible predictive risk testing is where GTG lives and it has now signed a 3-year Collaboration Agreement with high profile US-based researcher Translational Genomics Research Institute (TGen).

One ASX Med-Tech is Set to Transform The $100+Billion Cancer Diagnostic Market

MagSense is a unique, non-invasive, patent protected technology that fits into myriad addressable cancer diagnostic markets collectively worth $166 billion dollars and growing at 7% annually.

IMU’s Latest Cancer Treatment Acquisition Could Have Big Pharma Knocking

Imugene Limited (ASX:IMU) has negotiated to acquire a worldwide exclusive license to a promising OV developed at LA’s City of Hope Hospital.

GTG Validates Cancer Tests As it Looks to Global Expansion

What if there was a cost effective way for patients to assess their cancer risk and seek treatment? There is. Genetic Technologies (ASX:GTG; NASDAQ:GENE).

Could a Loxo Oncology Style Trial, Bring Loxo Style Results for PTX?

Clinical stage oncology company, Prescient Therapeutics (ASX:PTX) is in a fortunate position. It has two clinical candidates, four trials, and multiple possible pathways to market for its targeted therapies that address specific mutations that drive cancer and contribute to resistance.

Imugene Meets All Endpoints in Phase 1b Gastric Cancer Immuno-oncology Trial

Imugene (ASX:IMU) has now released results from the Phase 1b Gastric Cancer trial, showing that all dose levels of its HER-Vaxx cancer vaccine showed an increase in antibodies in patients.

Zero Safety Issues for IMU’s Immunotherapy Cancer Treatment: Phase II Trial Imminent

Imugene (ASX:IMU) is a clinical stage life sciences company on the cutting edge of this very field and is developing vaccines to boost and direct the immune system to target and attack cancer cells.

ASX Biotech Eyes International Distribution of Overlooked Cancer Drug

Today’s biotech junior is in the business of repurposing late-stage drug assets that have been overlooked by big pharma.

Top Results: BD1 Continues to Boost its Ovarian Cancer Detection Studies

BARD1 Life Sciences Limited (ASX:BD1) has both lung and ovarian cancer in its sights.

PTX Breast Cancer Trial Results Exceed Industry Expectations

Prescient Therapeutics (ASX:PTX) is looking to prove up its two breast cancer therapies, putting it ahead of the field in areas of high unmet need.

ASX Junior at the Forefront of Cancer Research Could be Set for a Blockbuster Year

This biotech appears to have cracked one of the holy grails of cancer research: it’s currently in human clinical trials with not one, but two innovative drugs which ‘turn off the switch’ that would otherwise allow cancerous cells to grow via the important Akt and Ras pathways.

IMU Picks up the Pace in Cancer Drug Treatment Development

It is difficult to understate the possible impact of the immuno-oncology therapies that the $33 million-capped Imugene (ASX: IMU) is currently developing. These therapies, if proven safe and successful, could have an undeniable real world positive effect for cancer patients.

Beating Cancer via Early Detection: ASX Stock Targeting Multiple Billion Dollar Markets

If you are going to beat cancer, your best bet is to catch it early. Of course, that’s easier said than done. By the time the symptoms of many cancers are apparent, a patient is often already in late stages of the disease. This is particularly true for lung cancer.

Could this ASX Cancer Therapy Junior Attract a Billion Dollar Big Pharma Deal?

One in every two Australians will be diagnosed with cancer by age 85. That’s a staggering statistic that has prompted a great deal of contemplation among doctors, patients and those affected in some way by the consequences of the disease. To try and combat the rise and spread of cancer, Big Pharma, along with smaller biotech companies are working on treatments and potential cures. One $30 million capped ASX junior may have a unique solution.

Are you a sophisticated investor?
Find out more
Please note: Raisebook is a related entity of S3 Consortium Pty Ltd as defined in Section 9 of the Corporations Act 2001.